Beginning Dec. 1, biopharmaceutical company Lonza will lay off 60 people at its manufacturing plant in Maryland, according to a Maryland WARN notice.
Lonza is a leading supplier to the pharmaceutical, biotech and specialty ingredients markets.
The layoffs are a result of a companywide realignment as the it builds four cell and gene therapy centers in the U.S., the Netherlands and Singapore, a company spokesperson told BioPharma Dive.
The Maryland plant will shift its focus from cell therapy production to bioscience solutions.
The layoffs are expected to occur over a one-year period.